Table 2.
EPA- and AA-derived eicosanoids in skin blister fluid at baseline and following 12-wk supplementation with 5 g/day of EPA-rich or control lipid
| Mean (SEM) (pg/μL)a | ||||||
|---|---|---|---|---|---|---|
| Baseline (n = 36)b | Control (n = 19) | EPA (n = 17) | ||||
| Unexposed | UVR exposed | Unexposed | UVR exposed | Unexposed | UVR exposed | |
| PGE2 | 10.2 (1.5) | 20.8 (2.4)††† | 10.7 (2.2) | 28.1 (5.4)†† | 6.0 (1.1)* | 19.9 (3.4)††† |
| PGE3 | 0.6 (0.1) | 1.1 (0.2)† | 0.6 (0.2) | 1.2 (0.3)† | 0.8 (0.2) | 3.1 (1.0)† |
| 12-HETE | 12.2 (1.3) | 35.4 (4.0)††† | 13.1 (2.9) | 51.4 (8.6)††† | 13.4 (3.8) | 50.3 (8.0)††† |
| 12-HEPE | 2.8 (0.3) | 4.5 (0.4)††† | 3.0 (0.6) | 6.4 (1.9)† | 5.9 (1.6) | 18.2 (3.4)†††,** |
a
Results are presented as picogram of eicosanoid per microlitre of blister fluid.
b
Baseline: combined treatment groups pre-supplementation.
†p < 0.05, ††p < 0.01, †††p < 0.001 compared to unexposed skin in the same group, *p < 0.05, **p < 0.01 compared to the corresponding skin (i.e. unexposed or UVR exposed) in the control group post-supplementation.